Information Bulletin was written and edited by Ken Fornataro, Tracy Swan, and Richard Jefferys with review and editorial assistance from Dr. Anthony Geraci, Mark Harrington, and Dr. Joseph Sonnabend. The latest edition of Treatment Review is available online, and in print. In addition, several Spanish language publicat
Dr. Anthony Geraci, Assistant Professor of Neurology, Mount Sinai School of Medicine, Division of NeuroAIDS, gave a presentation on neuropathy at a recent community forum sponsored by The AIDS Treatment Data Network (The Network), Community Research Initiative on AIDS (CRIA), Gay Men s Health Crisis (GMHC) and Treatmen
The full text of the alert regarding these changes is on the FDA Web site at: http://www.fda.gov/medwatch/safety/2000/virahp.pdf The labeling that comes with Viramune ( nevirapine ), a widely used anti-HIV drug that belongs to the class of drugs called NNRTIs, has recently been chang
The doctors that performed the study concluded that both Ritalin and Cylert can be useful treatments for HIV- related fatigue, but they stress that it s important to try and identify the cause of the fatigue first, in case it s a treatable condition like anemia (low red blood cells). The full title of this study is A R
The FDA has approved oral valganciclovir (Valcyte) for CMV retinitis treatment. This is the first oral treatment for both CMV retinitis induction and maintenance treatment. Currently, intravenous ganciclovir is used to treat CMV retinitis. After induction therapy, maintenance therapy is required. This usually requires
Every month The Network co-hosts community meetings with Treatment Action Group (TAG), Community Research Initiative on AIDS (CRIA), and Gay Men s Health Crisis (GMHC). The next forum is June 13th, from 7:00 to 9:00. The topic is HIV, Hepatitis and Liver Health. All forums are free and open to the public. The forums ta
The new guidelines are available on the Internet at: http://hivatis.org/trtgdlns.html. Since 1997, regularly updated guidelines on how to use anti-HIV drugs have been available in the US. These guidelines are produced by a panel of experts brought together by the US Public Health Service (PHS) and the Henry J. Kaiser F
New York City experienced case managers are invited to inquire about available positions at The Network by calling a(800)734-7104. Several staff changes have occurred at the Network over the past few months, temporarily delaying our publication schedule. In April, the Network welcomed Tracy Swan as the new Access Proje
To be eligible for this study you must be on a potent anti-retroviral drug regimen and have had an undetectable RNA viral load level (less than 500) for at least 12 consecutive months. You must have at least 500 CD4 cells and not have had less than 200 in the last 12 months. Participants must be negative for Hepatitis
This information is designed to support, not replace, the relationship that exists between you and your doctor.